Cyclacel Pharmaceuticals (CYCC) News Today $0.34 -0.07 (-17.25%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$0.32 -0.02 (-7.04%) As of 06:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENTJune 3, 2025 | globenewswire.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Reaches New 1-Year Low - Here's WhyCyclacel Pharmaceuticals (NASDAQ:CYCC) Hits New 1-Year Low - Time to Sell?May 16, 2025 | marketbeat.comCYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATEMay 15, 2025 | globenewswire.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Shares Down 7.8% - Time to Sell?Cyclacel Pharmaceuticals (NASDAQ:CYCC) Trading Down 7.8% - Here's WhyMay 14, 2025 | marketbeat.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.comStockNews.com assumed coverage on Cyclacel Pharmaceuticals in a research note on Saturday. They issued a "sell" rating on the stock.May 12, 2025 | marketbeat.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Shares Scheduled to Reverse Split on Monday, May 12thCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC - Free Report)'s stock is set to reverse split on the morning of Monday, May 12th. The 1-16 reverse split was announced on Wednesday, May 7th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, May 9th.May 10, 2025 | marketbeat.comCyclacel Pharmaceuticals, Inc.: Cyclacel Pharmaceuticals Announces Stock SplitMay 9, 2025 | finanznachrichten.deCYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLITMay 7, 2025 | globenewswire.comCYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.May 6, 2025 | globenewswire.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.comStockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals in a research report on Friday. They issued a "sell" rating on the stock.May 4, 2025 | marketbeat.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Short Interest UpdateCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC - Get Free Report) was the recipient of a large decrease in short interest in April. As of April 15th, there was short interest totalling 27,600 shares, a decrease of 50.4% from the March 31st total of 55,700 shares. Approximately 0.2% of the company's shares are short sold. Based on an average daily trading volume, of 364,700 shares, the days-to-cover ratio is presently 0.1 days.April 30, 2025 | marketbeat.comCyclacel Pharmaceuticals files to sell 35.18M shares of common stock for holdersApril 27, 2025 | markets.businessinsider.comCyclacel Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:CYCC | BenzingaApril 27, 2025 | benzinga.comCyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business UpdateApril 2, 2025 | globenewswire.comCyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred StockMarch 24, 2025 | globenewswire.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) CEO Sells $5,838,864.60 in StockMarch 1, 2025 | insidertrades.comCyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive LeadershipFebruary 27, 2025 | globenewswire.comCyclacel Pharmaceuticals adjusts shareholder rights, amends stockFebruary 12, 2025 | msn.comCyclacel stock plunges to 52-week low of $0.31 amid market challengesFebruary 11, 2025 | msn.comCyclacel Pharmaceuticals Restructures Leadership and Financial StrategyJanuary 7, 2025 | markets.businessinsider.comCyclacel announces agreement for acquisition of preferred stockJanuary 4, 2025 | markets.businessinsider.comDavid Lazar acquires Cyclacel Pharmaceuticals preferred stock, becomes interim CEO; stock jumpsJanuary 3, 2025 | msn.comCyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David LazarJanuary 3, 2025 | globenewswire.comCyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating CostsDecember 5, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports Q3 2024 Financial ResultsNovember 19, 2024 | markets.businessinsider.comCyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross ProceedsNovember 14, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross ProceedsNovember 13, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comCyclacel Pharmaceuticals granted extension for regain Nasdaq complianceOctober 25, 2024 | markets.businessinsider.comCyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard RuleOctober 24, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumOctober 23, 2024 | globenewswire.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Stock, Insider Trading ActivityOctober 20, 2024 | benzinga.comCyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumOctober 9, 2024 | globenewswire.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comCyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 StudySeptember 25, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comCyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting LetterSeptember 3, 2024 | globenewswire.comCyclacel Pharmaceuticals to Release Second Quarter 2024 Financial ResultsAugust 7, 2024 | globenewswire.comCyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical CompositionsJune 26, 2024 | globenewswire.comCyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingJune 4, 2024 | globenewswire.comCYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2024May 14, 2024 | investorplace.comCyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsMay 8, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesMay 2, 2024 | globenewswire.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?April 30, 2024 | msn.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?April 30, 2024 | investorplace.comCyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesApril 30, 2024 | globenewswire.comCyclacel Pharmaceuticals Shares Up 72% After Hours on Withdrawal of OfferingApril 29, 2024 | marketwatch.comCyclacel Pharmaceuticals Shares Hit All-Time Low on Planned Equity SaleApril 26, 2024 | marketwatch.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near FutureApril 25, 2024 | finance.yahoo.comCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for CancerApril 1, 2024 | globenewswire.com Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address CYCC Media Mentions By Week CYCC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYCC News Sentiment▼1.870.90▲Average Medical News Sentiment CYCC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYCC Articles This Week▼10▲CYCC Articles Average Week Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BioVie News Today Synergy CHC Corp. (Uplisting) News Today Mannatech News Today BioLineRx News Today Sol-Gel Technologies News Today Marker Therapeutics News Today Cingulate News Today Cognition Therapeutics News Today Longeveron News Today Lipocine News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYCC) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYCC Stock Free CYCC Stock Alerts